REPORTING FROM ACC 2018
He sees the ACALM findings as hypothesis generating, serving to help lay the groundwork for future clinical trials of vaccine or anti-inflammatory antibiotic therapies.
Dr. Carter reported having no financial conflicts related to his presentation.
SOURCE: Carter P. ACC 2018, Abstract 1325M-0.
© Frontline Medical Communications 2018-2021. Reprinted with permission, all rights reserved.
The incidence of patients with IVDU-associated endocarditis increased 630% from 2014 to 2018.
Six cases of a rare but serious event in patients who got the J&J vaccine are being reviewed.
"We believe a systematic way of addressing this risk is best, with every patient hospitalized with COVID-19 receiving some type of thromboprophylaxis," authors of a review article say.
Most attention has focused on the sickest patients, leaving less severe cases to fall through the cracks.
